Insights from 2023 ASH Annual Meeting

 

MDS and MPN
21:52

Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Implications"

FEATURING Douglas Tremblay
  • 402 views
  • January 26, 2024
10:02

Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Takeaways"

FEATURING Ruben Mesa
  • 359 views
  • January 19, 2024
  • 3
12:38

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "LIMBER-103 Study - BETi INCB057643 in Pts With R/R MF and Other Advanced Myeloid Neoplasms"

FEATURING Justin Watts
  • 49 views
  • January 19, 2024
08:18

Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

FEATURING Amy Zhou
  • 901 views
  • January 8, 2024
  • 5
05:44

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Study of Add-on Therapy With CK0804 in Patients With MF With a Suboptimal Response to Ruxolitinib"

FEATURING Lucia Masarova
  • 29 views
  • December 20, 2023
12:21

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "PIM1 Kinase Inhibitor TP-3654 for R/R Myelofibrosis"

FEATURING Lindsay Rein
  • 37 views
  • December 19, 2023
11:20

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Validation of the Composite CR Definitions in the IWG 2023 Criteria in Patients With HR-MDS Treated With HMAs"

FEATURING Jan Bewersdorf
  • 108 views
  • December 19, 2023
  • 1
13:24

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MATTERHORN Study - Efficacy & Safety of Roxadustat for Treatment of Anemia in Patients With LR-MDS With Low RBC Transfusion Burden"

FEATURING Moshe Mittelman
  • 68 views
  • December 19, 2023
06:46

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Guadecitabine in Higher-Risk MDS and CMML Under the IWG 2023 Criteria"

FEATURING Samuel Urrutia
  • 63 views
  • December 17, 2023
06:38

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "FREEDOM2 Study of Fedratinib in Patients With MF Previously Treated With Ruxolitinib"

FEATURING Claire Harrison
  • 90 views
  • December 17, 2023
10:40

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Durable Clinical Benefit With KER-050 (Elritercept) Treatment in a Ph2 Study in Patients With Lower-Risk MDS"

FEATURING Maria Diez-Campelo
  • 31 views
  • December 14, 2023
06:51

Insights from 2023 ASH Annual Meeting

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thrombocytopenia in Myelofibrosis

FEATURING Douglas Tremblay
  • 432 views
  • December 13, 2023
  • 1